Tenofir alaphenamid will be used for therapy of hepatitis B news European regulators registered the drug tenofovir alafenamide (tenofovir alafenamide) for the treatment of patients with viral hepatitis B. The drug company Gilead will enter the market under the trade name Vemlidy (Vemlidy), writes PharmaTimes. Control authorities allowed the use of a new drug in patients older than 12 years with a body weight of at least 35 kg. Tenofovir alaphenamide has already received marketing authorization in the USA (November 2016) and in Japan (December 2016).Previously, tenofovir alafenamide was registered as part of a combination drug against HIV. The efficacy and safety of tenofovir alafenamide in the treatment of hepatitis B virus has been demonstrated in clinical research among patients undergoing and not previously treated. In both CI, primary endpoints of the study were successfully achieved, which consisted in reducing the level of hepatitis B virus DNA to <29 IU / ml. Tenofovir alafenamide is a prodrug of tenofovir. The mechanism of action of tenofovir alaphenamid is similar to tenofovir, however comparable antiviral activity of tenofovir alafenamide is observed when 10 times less doses are administered. It has also been shown that tenofovir alaphenamib has a less negative effect on bone mineral density than tenofovir. A source: Remedium